This Strategic Business Plan (SBP) describes the strategic direction of the Medicines Evaluation Board (MEB) in the coming period from 2020 to 2024. We used the previous SBP to plot a course to connect with medical practice, for example by improving the provision of information. We now wish to continue along that course in line with our core values – scientific, vigilant and connected – with the aim to improve confidence in medicines.